20 Dec 2019 09:00
Notice of Interim Results
Oxford, UK; 20 December 2019: Sensyne Health plc (LSE: SENS), the British clinical AI technology company, will announce its Interim Results for the 6 months ended 31 October 2019 on Tuesday 21 January 2020.
Lord (Paul) Drayson, Chief Executive Officer, and Lorimer Headley, Chief Financial Officer, will host a briefing for analysts at 12.00pm GMT on the day of the results at 1 Moorgate Place, London, EC2R 6EA.
A live webcast of the meeting, with the presentation slides, will be available via the Company's website.
-ENDS-
For more information please contact:
Sensyne Health (www.sensynehealth.com) | +44 (0) 330 058 1845 |
Lord (Paul) Drayson, Chief Executive Officer |
|
Lorimer Headley, Chief Financial Officer |
|
|
|
Peel Hunt LLP (Nominated Adviser and Joint Broker) | + 44 (0) 20 7418 8900 |
Dr Christopher Golden |
|
James Steel |
|
Oliver Jackson |
|
|
|
Liberum (Joint Broker) | + 44 (0) 20 3100 2000 |
Bidhi Bhoma |
|
Euan Brown |
|
|
|
Consilium Strategic Communications | +44 20 3709 5700 |
Mary-Jane Elliott |
|
Sukaina Virji |
|
Melissa Gardiner |
|
sensynehealth@consilium-comms.com |
|
About Sensyne Health
Sensyne Health plc is a clinical AI company that works in partnership with the NHS to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L). For more information, please visit: www.sensynehealth.com
SENS.L (SENS)